A novel factor distinct from E2F mediates C-MYC promoter activation through its E2F element during exit from quiescence

Carcinogenesis

Volumn 30, Issue 3, 2009, Pages 440-448

  Álvaro Blanco, Josué ^a,b   MartÍnez gac, Lorena ^a,b   Calonge, Esther ^b   Rodríguez Martínez, MarÍa ^a   Molina Privado, Irene ^a   Redondo, Juan M ^c   Alcamí, José ^a   Flemington, Erik K ^d   Campanero, Miguel R ^a  

^a CSIC   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^d TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; MYC PROTEIN; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F;

ARTICLE; BINDING SITE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DNA BINDING; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MOLECULAR WEIGHT; PHASE TRANSITION; PRIORITY JOURNAL; PROMOTER REGION; TRANSACTIVATION; TRANSITIONAL CELL CARCINOMA;

ANIMALS; BINDING SITES; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DNA-BINDING PROTEINS; E2F TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION; HUMANS; MICE; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MYC; REGULATORY SEQUENCES, NUCLEIC ACID; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION;

EID: 62349112149     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp002     Document Type: Article

References (41)

1. Adhikary,S. et al. (2005) Transcriptional regulation and transformation by Myc proteins. Nat. Rev. Mol. Cell Biol., 6 635-645.
2. Chung,H.J. et al. (2005) c-myc expression: Keep the noise down!. Mol. Cells, 20, 157-166.
3. Dang,C.V. (1999) c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol. Cell. Biol., 19, 1-11.
4. Bieche,I. et al. (1999) Quantitation of MYC gene expression in sporadic breast tumors with a real-time reverse transcription-PCR assay. Cancer Res., 59, 2759-2765.
5. Mai,S. (1994) Overexpression of c-myc precedes amplification of the gene encoding dihydrofolate reductase. Gene, 148, 253-260.
6. Mai,S. et al. (1996) c-Myc overexpression associated DHFR gene amplification in hamster, rat, mouse and human cell lines. Oncogene 12, 277-288.
7. Cerni,C. et al. (1986) c-myc and functionally related oncogenes induce both high rates of sister chromatid exchange and abnormal karyotypes in rat fibroblasts. Curr. Top. Microbiol. Immunol., 132, 193-201.
8. Chernova,O.B. et al. (1998) MYC abrogates p53-mediated cell cycle arrest in N-(phosphonacetyl)-L-aspartate-treated cells, permitting CAD gene amplification. Mol. Cell. Biol., 18, 536-545.
9. Mai,S. et al. (1996) Genomic instability in MycER-activated Rat1A-MycER cells. Chromosome Res., 4, 365-371.
10. Rockwood,L.D. et al. (2002) Genomic instability in mouse Burkitt lymphoma is dominated by illegitimate genetic recombinations, not point mutations. Oncogene, 21, 7235-7240.
11. Wierstra,I. et al. (2008) The c-myc promoter: Still MysterY and challenge. Adv. Cancer Res., 99C, 113-333.
12. Kelly,K. et al. (1983) Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor. Cell, 35, 603-610.
13. Mudryj,M. et al. (1990) A role for the adenovirus inducible E2F transcription factor in a proliferation dependent signal transduction pathway. EMBO J., 9, 2179-2184.
14. Polack,A. et al. (1991) The intron enhancer of the immunoglobulin kappa gene activates c-myc but does not induce the Burkitt-specific promoter shift. Oncogene, 6, 2033-2040.
15. Lavenu,A. et al. (1994) The cis-acting elements known to regulate c-myc expression ex vivo are not sufficient for correct transcription in vivo. Oncogene, 9, 527-536.
16. Mautner,J. et al. (1996) c-myc expression is activated by the immunoglobulin kappa-enhancers from a distance of at least 30 kb but not by elements located within 50 kb of the unaltered c-myc locus in vivo. Oncogene, 12, 1299-1307.
17. Hortnagel,K. et al. (1995) The role of immunoglobulin kappa elements in c-myc activation. Oncogene, 10, 1393-1401.
18. McClellan,K.A. et al. (2007) Specific in vivo roles for E2Fs in differentiation and development. Cell Cycle, 6, 2917-2927.
19. Flemington,E.K. et al. (1993) E2F-1 mediated transactivation is inhibited by complex formation with the retinoblastoma susceptibility gene product. Proc. Natl Acad. Sci. USA, 90, 6914-6918.
20. Helin,K. et al. (1993) Inhibition of E2F-1 transactivation by direct binding of the retinoblastoma protein. Mol. Cell. Biol., 13, 6501-6508.
21. Blais,A. et al. (2007) E2F-associated chromatin modifiers and cell cycle control. Curr. Opin. Cell Biol., 19, 658-662.
22. Johnson,D.G. et al. (1998) Role of E2F in cell cycle control and cancer. Front. Biosci., 3, 447-458.
23. Hann,S.R. et al. (1985) c-myc oncogene protein synthesis is independent of the cell cycle in human and avian cells. Nature, 314, 366-369.
24. Thompson,C.B. et al. (1985) Levels of c-myc oncogene mRNA are invariant throughout the cell cycle. Nature, 314, 363-366.
25. Campanero,M.R. et al. (1993) ICAM-3 interacts with LFA-1 and regulates the LFA-1/ICAM-1 cell adhesion pathway. J. Cell Biol., 123, 1007-1016.
26. Campanero,M.R. et al. (1999) Distinct cellular factors regulate the c-myb promoter through its E2F element. Mol. Cell. Biol., 19, 8442-8450.
27. Thompson,C.B. et al. (1992) Cis-acting sequences required for inducible interleukin-2 enhancer funciton bind a novel ets-related protein, Elf-1. Mol. Cell. Biol., 12, 1043-1053.
28. Campanero,M.R. et al. (2008) The histone deacetylase inhibitor trichostatin A induces GADD45 gamma expression via Oct and NF-Y binding sites. Oncogene, 27, 1263-1272.
29. Campanero,M.R. et al. (2000) CpG methylation as a mechanism for the regulation of E2F activity. Proc. Natl Acad. Sci. USA, 97 6481-6486.
30. Campanero,M.R. et al. (1997) Regulation of E2F through ubiquitin-proteasome-dependent degradation: Stabilization by the pRB tumor suppressor protein. Proc. Natl Acad. Sci. USA, 94, 2221-2226.
31. Alcami,J. et al. (1995) Absolute dependence on kappa B responsive elements for initiation and Tat-mediated amplification of HIV transcription in blood CD4 T lymphocytes. EMBO J., 14, 1552-1560.
32. Shirodkar,S. et al. (1992) The transcription factor E2F interacts with the retinoblastoma product and a p107-cyclin A complex in a cell cycle regulated manner. Cell, 68, 157-166.
33. de Bruin,A. et al. (2003) Identification and characterization of E2F7, a novel mammalian E2F family member capable of blocking cellular proliferation. J. Biol. Chem., 278, 42041-42049.
34. Di Stefano,L. et al. (2003) E2F7, a novel E2F featuring DP-independent repression of a subset of E2F-regulated genes. EMBO J. 22, 6289-6298.
35. Roussel,M.F. et al. (1994) Dual control of myc expression through a single DNA binding site targeted by ets family proteins and E2F-1. Oncogene, 9, 405-415.
36. Kiuchi,N. et al. (1999) STAT3 is required for the gp130-mediated full activation of the c-myc gene. J. Exp. Med., 189, 63-73.
37. Buettner,R. et al. (2002) Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin. Cancer Res., 8, 945-954.
38. Turkson,J. et al. (2000) STAT proteins: Novel molecular targets for cancer drug discovery. Oncogene, 19, 6613-6626.
39. Weber-Nordt,R.M. et al. (1996) Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood, 88 809-816.
40. Buchholz,M. et al. (2006) Overexpression of c-myc in pancreatic cancer caused by ectopic activation of NFATc1 and the Ca2+/calcineurin signaling pathway. EMBO J., 25, 3714-3724.
41. Iniguez,M.A. et al. (2000) An essential role of the nuclear factor of activated T cells in the regulation of the expression of the cyclooxygenase-2 gene in human T lymphocytes. J. Biol. Chem., 275, 23627-23635.